The Advisory Committee on Immunization Practices’ (ACIP) voted on February 21 to unanimously recommend HEPLISAV-B™ for use among individuals age 18 years and older to prevent hepatitis B infection (HBV). The Hepatitis B Foundation welcomes the use of the new vaccine, which is expected to increase immunization rates for adults in the United States. HEPLISAV-B™ was approved for use by the FDA on July 28, 2017. It is the first new hepatitis B vaccine in more than 25 years, and the only two dose vaccine for the prevention of infection.

Read more here.

Click to read more on HEPLISAV-B,  clinical trials of Hepsilav-B, the potential impact of Hepsilav-B approval, and Dynavax’s press release following the vote.

©2019 HepFree.NYC. All rights reserved. Site by Lookit®

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you. Thank you.

Sending
or

Log in with your credentials

Forgot your details?